Company / R&D per Share
SAB Biotherapeutics, Inc. R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.26
FY2025
5-year range
$1.07 / $7.23
FY2021-FY2025
Trend
+81.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $7.23 to $3.26 over the past 2 years.
Based on SEC 10-K filings.
3.26 in FY2025 with a 3-year CAGR of +13.9%.
Declined from $7.23 to $3.26 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 81.9% year-over-year.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.26 | +81.9% |
| FY2024 | $1.79 | -75.2% |
| FY2023 | $7.23 | +228.4% |
| FY2022 | $2.20 | +104.9% |
| FY2021 | $1.07 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026